Xencor Unveils Preliminary Findings for XmAb819, a Novel ENPP3 x CD3 Bispecific T-Cell Engager Targeting Clear Cell Renal Cell Carcinoma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Should l Buy XNCR?
Source: Newsfilter
XmAb819 Clinical Trial Results: XmAb819, a bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC), shows a 25% overall response rate and a well-tolerated safety profile in heavily pretreated patients during a Phase 1 study.
Dose Expansion and Future Plans: The first dose-expansion cohort has been selected, with ongoing dose escalation to determine the recommended Phase 3 dose, aiming to initiate a pivotal study in 2027.
Safety Profile and Adverse Events: The most common treatment-emergent adverse events were mild to moderate, including cytokine release syndrome and rash, with a few cases of Grade 3 events; no Grade 5 events were reported.
Webcast Announcement: Xencor will host a webcast to discuss the initial results, accessible through their website, with a recording available for 30 days.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XNCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XNCR
Wall Street analysts forecast XNCR stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.420
Low
20.00
Averages
26.25
High
30.00
Current: 11.420
Low
20.00
Averages
26.25
High
30.00
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Decline Amid Ongoing Iran Conflict
- Market Performance: On Tuesday, the S&P 500 Index fell by 0.37%, the Dow Jones Industrial Average decreased by 0.18%, and the Nasdaq 100 Index dropped by 0.77%, reflecting investor concerns over the ongoing conflict in Iran and a general decline in market sentiment.
- Oil Price Fluctuations: WTI crude oil prices surged over 4%, reaching elevated levels due to Iran's missile and drone strikes on Israel and US bases, raising fears about energy supply disruptions that could impact global economic recovery.
- Economic Data: Despite market pressures, Q4 nonfarm productivity remained at 1.8%, while unit labor costs were revised up to 4.4%, exceeding expectations, indicating resilience in the economic fundamentals that may provide some support to the stock market.
- International Tensions: Reports of Saudi Arabia and the UAE aligning with the Iran conflict have heightened market anxiety, as investors are closely monitoring the potential for increased US military deployment, which could escalate tensions and affect global market stability.
See More
US Stocks Decline Amid Ongoing Iran Conflict
- Market Movement: The S&P 500 Index is down 0.16%, while the Dow Jones Industrial Average is up 0.13%, and the Nasdaq 100 Index has decreased by 0.50%, reflecting investor concerns over the ongoing Iran conflict, which is dampening market sentiment.
- Rising Energy Prices: WTI crude oil prices have surged over 4% due to Iran's missile strikes on Israel and US bases, which not only limits stock market declines but also raises inflation expectations, potentially influencing future monetary policy decisions.
- Economic Data Performance: The US Q4 nonfarm productivity remained unchanged at 1.8%, while unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating economic resilience that may support the stock market.
- International Tensions Impact: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, which increases market concerns about future geopolitical risks and drives investors towards safer assets.
See More
US Stocks Decline Amid Ongoing Iran Conflict
- Market Decline: The S&P 500 Index fell by 0.80%, the Dow Jones Industrial Average by 0.83%, and the Nasdaq 100 by 0.98%, reflecting investor concerns over the ongoing Iran conflict, which may dampen market sentiment and affect short-term investment decisions.
- Rising Oil Prices: WTI crude oil prices surged over 4% due to Iran's missile strikes on Israel and US bases, exacerbating global supply chain tensions and potentially raising inflation expectations in the coming months, which could influence the Fed's monetary policy.
- Mixed Economic Data: Q4 nonfarm productivity remained unchanged at 1.8%, but unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating rising labor costs that may pressure corporate profits and subsequently impact stock market performance.
- International Tensions: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, and the high uncertainty surrounding future developments will continue to affect investor confidence and market volatility.
See More
Xencor Lowers Outlook After Royalty Dispute
- Stock Price Decline: Xencor (XNCR) shares fell approximately 8% on Thursday, primarily due to the company's lowered outlook following a royalty dispute with AstraZeneca's subsidiary Alexion Pharmaceuticals, indicating market concerns about future earnings.
- Royalty Revenue Adjustment: Xencor stated that Alexion has informed the company it will no longer owe additional royalties related to Ultomiris net sales in the U.S., although payments for sales outside the U.S. will continue, potentially leading to future revenue uncertainty.
- Cash Flow Forecast Downgrade: The company updated its year-end cash guidance, projecting cash, cash equivalents, and marketable debt securities to reach $380 million to $400 million by year-end, down from the previous estimate of $400 million to $430 million, reflecting a cautious outlook on future operations.
- Shortened Operating Runway: Xencor's revised operating runway forecast has also been shortened, now expected to last until mid-2028, down from prior guidance, indicating increased financial pressure on the company amid the royalty dispute.
See More
Xencor Lowers Revenue Outlook for Ultomiris Royalties
- Revenue Outlook Revision: Xencor Inc. announced a revision of its revenue outlook for royalties tied to Ultomiris, as Alexion Pharmaceuticals stated it does not owe additional royalties on Ultomiris sales, which will directly impact Xencor's future cash flow and profitability.
- Cash Flow Forecast Adjustment: Xencor lowered its 2026 cash outlook from $400 million–$430 million to $380 million–$400 million, although it still expects its cash runway to support operations into mid-2028, indicating some financial pressure on the company.
- Analyst Perspective: William Blair holds a slightly negative view on Xencor's outlook, yet anticipates that clinical trial updates in 2026 will serve as more impactful catalysts, thus reiterating an Outperform rating, reflecting cautious optimism about the company's long-term potential.
- Technical Analysis Signals: Xencor's stock is currently trading below its 20-day and 100-day simple moving averages, indicating short-term weakness; despite an 83% increase in share price over the past 12 months, the mixed signals from RSI and MACD suggest investors should proceed with caution.
See More
Xencor Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Xencor reported a Q4 GAAP EPS of -$0.09, surpassing expectations by $0.50, indicating resilience in profitability despite ongoing financial challenges.
- Significant Revenue Decline: The company’s revenue of $28.24 million represents a 46.5% year-over-year decrease, missing market expectations, which may impact investor confidence in a competitive biopharmaceutical landscape.
- Strong Cash Reserves: As of December 31, 2025, Xencor held $610.8 million in cash, cash equivalents, and marketable securities, down from $706.7 million in 2024, reflecting cautious financial management amid operational challenges.
- Optimistic Partnership Outlook: The late-stage trial success of the lymphoma therapy partnered with Incyte, along with its EU approval, suggests potential growth opportunities for Xencor in drug development and market expansion.
See More
US Stocks Decline Amid Ongoing Iran Conflict
- Market Performance: On Tuesday, the S&P 500 Index fell by 0.37%, the Dow Jones Industrial Average decreased by 0.18%, and the Nasdaq 100 Index dropped by 0.77%, reflecting investor concerns over the ongoing conflict in Iran and a general decline in market sentiment.
- Oil Price Fluctuations: WTI crude oil prices surged over 4%, reaching elevated levels due to Iran's missile and drone strikes on Israel and US bases, raising fears about energy supply disruptions that could impact global economic recovery.
- Economic Data: Despite market pressures, Q4 nonfarm productivity remained at 1.8%, while unit labor costs were revised up to 4.4%, exceeding expectations, indicating resilience in the economic fundamentals that may provide some support to the stock market.
- International Tensions: Reports of Saudi Arabia and the UAE aligning with the Iran conflict have heightened market anxiety, as investors are closely monitoring the potential for increased US military deployment, which could escalate tensions and affect global market stability.
See More
US Stocks Decline Amid Ongoing Iran Conflict
- Market Movement: The S&P 500 Index is down 0.16%, while the Dow Jones Industrial Average is up 0.13%, and the Nasdaq 100 Index has decreased by 0.50%, reflecting investor concerns over the ongoing Iran conflict, which is dampening market sentiment.
- Rising Energy Prices: WTI crude oil prices have surged over 4% due to Iran's missile strikes on Israel and US bases, which not only limits stock market declines but also raises inflation expectations, potentially influencing future monetary policy decisions.
- Economic Data Performance: The US Q4 nonfarm productivity remained unchanged at 1.8%, while unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating economic resilience that may support the stock market.
- International Tensions Impact: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, which increases market concerns about future geopolitical risks and drives investors towards safer assets.
See More
US Stocks Decline Amid Ongoing Iran Conflict
- Market Decline: The S&P 500 Index fell by 0.80%, the Dow Jones Industrial Average by 0.83%, and the Nasdaq 100 by 0.98%, reflecting investor concerns over the ongoing Iran conflict, which may dampen market sentiment and affect short-term investment decisions.
- Rising Oil Prices: WTI crude oil prices surged over 4% due to Iran's missile strikes on Israel and US bases, exacerbating global supply chain tensions and potentially raising inflation expectations in the coming months, which could influence the Fed's monetary policy.
- Mixed Economic Data: Q4 nonfarm productivity remained unchanged at 1.8%, but unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating rising labor costs that may pressure corporate profits and subsequently impact stock market performance.
- International Tensions: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, and the high uncertainty surrounding future developments will continue to affect investor confidence and market volatility.
See More
Xencor Lowers Outlook After Royalty Dispute
- Stock Price Decline: Xencor (XNCR) shares fell approximately 8% on Thursday, primarily due to the company's lowered outlook following a royalty dispute with AstraZeneca's subsidiary Alexion Pharmaceuticals, indicating market concerns about future earnings.
- Royalty Revenue Adjustment: Xencor stated that Alexion has informed the company it will no longer owe additional royalties related to Ultomiris net sales in the U.S., although payments for sales outside the U.S. will continue, potentially leading to future revenue uncertainty.
- Cash Flow Forecast Downgrade: The company updated its year-end cash guidance, projecting cash, cash equivalents, and marketable debt securities to reach $380 million to $400 million by year-end, down from the previous estimate of $400 million to $430 million, reflecting a cautious outlook on future operations.
- Shortened Operating Runway: Xencor's revised operating runway forecast has also been shortened, now expected to last until mid-2028, down from prior guidance, indicating increased financial pressure on the company amid the royalty dispute.
See More
Xencor Lowers Revenue Outlook for Ultomiris Royalties
- Revenue Outlook Revision: Xencor Inc. announced a revision of its revenue outlook for royalties tied to Ultomiris, as Alexion Pharmaceuticals stated it does not owe additional royalties on Ultomiris sales, which will directly impact Xencor's future cash flow and profitability.
- Cash Flow Forecast Adjustment: Xencor lowered its 2026 cash outlook from $400 million–$430 million to $380 million–$400 million, although it still expects its cash runway to support operations into mid-2028, indicating some financial pressure on the company.
- Analyst Perspective: William Blair holds a slightly negative view on Xencor's outlook, yet anticipates that clinical trial updates in 2026 will serve as more impactful catalysts, thus reiterating an Outperform rating, reflecting cautious optimism about the company's long-term potential.
- Technical Analysis Signals: Xencor's stock is currently trading below its 20-day and 100-day simple moving averages, indicating short-term weakness; despite an 83% increase in share price over the past 12 months, the mixed signals from RSI and MACD suggest investors should proceed with caution.
See More
Xencor Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Xencor reported a Q4 GAAP EPS of -$0.09, surpassing expectations by $0.50, indicating resilience in profitability despite ongoing financial challenges.
- Significant Revenue Decline: The company’s revenue of $28.24 million represents a 46.5% year-over-year decrease, missing market expectations, which may impact investor confidence in a competitive biopharmaceutical landscape.
- Strong Cash Reserves: As of December 31, 2025, Xencor held $610.8 million in cash, cash equivalents, and marketable securities, down from $706.7 million in 2024, reflecting cautious financial management amid operational challenges.
- Optimistic Partnership Outlook: The late-stage trial success of the lymphoma therapy partnered with Incyte, along with its EU approval, suggests potential growth opportunities for Xencor in drug development and market expansion.
See More
